Literature DB >> 20172575

Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses.

Vinita S Chauhan1, Samantha R Furr, David G Sterka, Daniel A Nelson, Megan Moerdyk-Schauwecker, Ian Marriott, Valery Z Grdzelishvili.   

Abstract

Vesicular stomatitis virus (VSV) infection of mice via intranasal administration results in a severe encephalitis with rapid activation and proliferation of microglia and astrocytes. We have recently shown that these glial cells express RIG-I and MDA5, cytosolic pattern recognition receptors for viral RNA. However, it is unclear whether VSV can replicate in glial cells or if such replication is required for their inflammatory responses. Here we demonstrate that primary microglia and astrocytes are permissive for VSV infection and limited productive replication. Importantly, we show that viral replication is required for robust inflammatory mediator production by these cells. Finally, we have confirmed that in vivo VSV administration can result in viral infection of glial cells in situ. These results suggest that viral replication within resident glial cells might play an important role in CNS inflammation following infection with VSV and possibly other neurotropic nonsegmented negative-strand RNA viruses. Copyright 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172575     DOI: 10.1016/j.virol.2010.01.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.

Authors:  Tomasz Tomczyk; Grażyna Wróbel; Radosław Chaber; Iwona Siemieniec; Egbert Piasecki; Małgorzata Krzystek-Korpacka; Beata U Orzechowska
Journal:  J Innate Immun       Date:  2018-01-06       Impact factor: 7.349

Review 2.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

Review 3.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

4.  RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes.

Authors:  Samantha R Furr; Megan Moerdyk-Schauwecker; Valery Z Grdzelishvili; Ian Marriott
Journal:  Glia       Date:  2010-10       Impact factor: 7.452

5.  RIG-I is required for VSV-induced cytokine production by murine glia and acts in combination with DAI to initiate responses to HSV-1.

Authors:  Emma K Crill; Samantha R Furr-Rogers; Ian Marriott
Journal:  Glia       Date:  2015-07-03       Impact factor: 7.452

6.  Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Authors:  Anthony M Marchese; Carolina Chiale; Safiehkhatoon Moshkani; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2019-10-18       Impact factor: 2.607

7.  Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons.

Authors:  Sreeja Sarojini; Thana Theofanis; Carol Shoshkes Reiss
Journal:  DNA Cell Biol       Date:  2011-09-15       Impact factor: 3.311

8.  Astrocytes produce IL-19 in response to bacterial challenge and are sensitive to the immunosuppressive effects of this IL-10 family member.

Authors:  Ian D Cooley; Vinita S Chauhan; Miguel A Donneyz; Ian Marriott
Journal:  Glia       Date:  2014-05       Impact factor: 7.452

Review 9.  Understanding and altering cell tropism of vesicular stomatitis virus.

Authors:  Eric Hastie; Marcela Cataldi; Ian Marriott; Valery Z Grdzelishvili
Journal:  Virus Res       Date:  2013-06-22       Impact factor: 3.303

10.  Alpha beta-crystallin expression and presentation following infection with murine gammaherpesvirus 68.

Authors:  Vinita S Chauhan; Daniel A Nelson; Ian Marriott; Kenneth L Bost
Journal:  Autoimmunity       Date:  2013-04-16       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.